NBY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NovaBay Pharmaceuticals Inc (NBY) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with declining net income and EPS, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. The technical indicators and options data also do not support a compelling entry point at this time.
The MACD is positive and expanding, indicating a potential bullish momentum. However, the RSI is neutral at 22.874, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.311, and resistance is at 3.191. The stock is trading below its pivot point, suggesting weakness.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Weak financial performance in Q3 2025, with declining net income (-41.68% YoY) and EPS (-88.54% YoY). No recent news or events to drive positive sentiment.
In Q3 2025, revenue remained flat at $521,000 (0.00% YoY). Net income dropped significantly to -$1,293,000 (-41.68% YoY), and EPS fell sharply to -1.1 (-88.54% YoY). Gross margin slightly improved to 8.06 (0.00% YoY). Overall, the financials indicate poor growth and profitability trends.
No recent analyst ratings or price target changes available for NBY.
